Merck (MRK) reported third-quarter 2024 adjusted earnings of $1.57 per share, which beat the Zacks Consensus Estimate of $1.50. Earnings declined 26% year over year on a reported basis and 23% excluding foreign exchange (Fx) impact due to one-time charges incurred by the company related to business development.Revenues rose 4% year over year (7% excluding Fx) to $16.66 billion. Sales also beat the Zacks Consensus Estimate of $16.55 billion.All sales growth numbers discussed below are on a year-over-year bas ...

For the quarter ended September 2024, Merck (MRK) reported revenue of $16.66 billion, up 4.4% over the same period last year. EPS came in at $1.57, compared to $2.13 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $16.55 billion, representing a surprise of +0.65%. The company delivered an EPS surprise of +4.67%, with the consensus EPS estimate being $1.50.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they ...

Merck (MRK) came out with quarterly earnings of $1.57 per share, beating the Zacks Consensus Estimate of $1.50 per share. This compares to earnings of $2.13 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 4.67%. A quarter ago, it was expected that this pharmaceutical company would post earnings of $2.16 per share when it actually produced earnings of $2.28, delivering a surprise of 5.56%.Over the last four quarters, the compan ...

文章核心观点 - 该公司是一家提供金融新闻和在线广播的公司,拥有遍布全球主要金融中心的新闻团队[1][2] - 公司专注于中小市值公司的报道,同时也关注蓝筹股、大宗商品和其他投资主题[2] - 公司的新闻内容涵盖多个行业,包括生物科技、制药、采矿、天然资源、电池金属、石油天然气、加密货币和新兴数字技术等[3] - 公司采用前瞻性的技术手段,如使用自动化和软件工具(包括生成式AI)来辅助内容创作,但所有内容仍由人工编辑和撰写[4] 根据相关目录分别进行总结 公司概况 - 公司提供金融新闻和在线广播服务,拥有遍布全球主要金融中心的新闻团队[1][2] - 公司专注于中小市值公司的报道,同时也关注蓝筹股、大宗商品和其他投资主题[2] 行业覆盖 - 公司的新闻内容涵盖多个行业,包括生物科技、制药、采矿、天然资源、电池金属、石油天然气、加密货币和新兴数字技术等[3] 技术应用 - 公司采用前瞻性的技术手段,如使用自动化和软件工具(包括生成式AI)来辅助内容创作,但所有内容仍由人工编辑和撰写[4]

Exhibit 99.2 MERCK & CO., INC. CONSOLIDATED STATEMENT OF OPERATIONS - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 1a 2024 2023 % Change | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-------------------------------------|---------------------|----------------------|----------------|---------------------|------------------|-------------------|-------------------------------|-------------------------------|----------------------|-- ...

The exterior view of the entrance to Merck headquarters in Rahway, New Jersey, on Feb. 5, 2024.Merck on Thursday reported third-quarter revenue and adjusted earnings that topped expectations as the company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health business. But Merck's vaccine that prevents cancer from HPV, the most common sexually transmitted infection in the U.S., posted another quarter of lighter-than-expected sales. Revenue from the sh ...

文章核心观点 - 默克公司(Merck)即将公布季度财报,预计每股收益为1.50美元,同比下降29.6% [1] - 分析师预测公司收入为165.4亿美元,同比增长3.7% [1] - 过去30天内,分析师对本季度每股收益预测下调了2.1% [1] 关键指标总结 肿瘤业务 - 联盟收入-Lynparza预计为3.46亿美元,同比增长15.7% [4] - Keytruda销售额预计达73.8亿美元,同比增长16.5% [4] - 联盟收入-Lenvima预计为2.75亿美元,同比增长5.8% [5] - Keytruda国际销售额预计为29.3亿美元,同比增长15.2% [6] - 联盟收入-Lynparza美国销售额预计为1.68亿美元,同比增长9.8% [7] - 联盟收入-Lynparza国际销售额预计为1.78亿美元,同比增长21.9% [7] - 联盟收入-Lenvima美国销售额预计为1.81亿美元,同比增长12.9% [8] - 联盟收入-Lenvima国际销售额预计为0.94亿美元,同比下降5.6% [8] 医院急诊业务 - Zerbaxa销售额预计为0.59亿美元,同比增长11.9% [4] - Bridion美国销售额预计为3.09亿美元,同比增长16.7% [5] - Zerbaxa美国销售额预计为0.32亿美元,同比增长12% [9] 糖尿病业务 - Janumet美国销售额预计为0.36亿美元,同比下降17.3% [6]

There's a lot to like here.No matter how well the stock market is performing, investors can always find some companies that aren't keeping pace with broader equities. This year, pharmaceutical giant Merck (MRK -1.79%) is it: The drugmaker's shares are down by 2% in 2024 while the broader S&P 500 is up by 21%.Even when we zoom out, Merck hasn't performed particularly well in recent years. The company has significantly trailed the S&P 500 over the past decade. Does that mean investors should stay away from Me ...

TROY, Mich., Oct. 25, 2024 /PRNewswire/ -- The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Merck & Co. (NYSE: MRK) as its "Stock to Study" and Ball Corp (NYSE: BALL) as its "Undervalued Stock" in the January 2025 issue for investors' informational and educational use. The organization remains concerned about the number of Americans who are investing for the future. "Too many Americans hesitate to invest, waiting for what they believe is the perfect moment, ...

If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio, or simply access the investment bank-grade financial models and research. I hope to see you there.Merck & Co., Inc. (NYSE: MRK ) will report its Q3 earnings next Thursday, 31st October. I covered the company shortly before Q2 earnings, assigning the stock a "Hold" rati ...